Assessment of Bortezomib (Alvocade ®) Efficacy & Safety in Newly Diagnosed

Updated 06/21/2024

Status Withdrawn

Clinical Trial Summary

Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04348006
Study type	Interventional
Source	Al-Rasheed University College
Contact
Status	Withdrawn
Phase	Phase 4
Start date	March 1, 2020
Completion date	July 30, 2021

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04052880` - Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM	Phase 2
	Active, not recruiting	`NCT03742297` - Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years	Phase 3
	Not yet recruiting	`NCT05558319` - NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide	Phase 3
	Recruiting	`NCT04891809` - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM	Phase 2
	Not yet recruiting	`NCT05561049` - Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
	Completed	`NCT01936532` - Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)	Phase 2
	Recruiting	`NCT05259553` - Biomarkers in Multiple Myeloma	N/A
	Completed	`NCT01809717` - Multiple Myeloma and Exercise	N/A
	Terminated	`NCT03733691` - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients	Phase 2
	Active, not recruiting	`NCT00405756` - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.	Phase 3
	Recruiting	`NCT05665140` - Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients	Phase 2/Phase 3
	Not yet recruiting	`NCT05088330` - A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM	N/A
	Active, not recruiting	`NCT03948035` - Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM	Phase 3
	Not yet recruiting	`NCT06348147` - Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation	Phase 2
	Recruiting	`NCT06324266` - Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation	Phase 2/Phase 3